With first clinical data due next year, Scribe to test IPO market: Finance Report

With its first gene silencing therapy now in clinical testing, in vivo CRISPR company Scribe has become the latest biotech to file for an IPO. The start-up, co-founded by gene editing pioneer Jennifer Doudna, entered the NASDAQ queue just before the July 4 holiday weekend began.

Scribe Therapeutics Inc. has begun first-in-human testing of its lead program, STX-1150, in Australia among patients at risk of atherosclerotic cardiovascular disease (ASCVD). The treatment uses Scribe’s Epigenetic Long-Term X-Repressor (ELXR) technology to suppress expression of PCSK9; the company expects initial data in 1H27...